Activation of both GIP and GLP-1 receptors by retatrutide probably contributed to the observed changes in circulating triglycerides, as treatment with the dual GIP/GLP-1 receptor agonist tirzepatide significantly reduced triglyceride levels by up to 29% at 52 weeks in a clinical trial in people with T2D and MASLD8. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.